美國食品藥物管理局批准新款 mRNA 流感疫苗
FDA approves new mRNA flu vaccine
Updated at: August 7, 2026 at 01:15 AM
2026年8月5日，美國食品藥物管理局(FDA)批准了mFlusiva，這是首款運用mRNA技術的流感疫苗，標誌著醫學領域達成了一項重要里程碑。
On August 5, 2026, the medical landscape reached a significant milestone when the U.S.
該疫苗由莫德納(Moderna)公司開發，代表了我們對抗季節性流感方式的重大轉變。
FDA approved mFlusiva, the first influenza vaccine powered by mRNA technology.
mFlusiva最初設計用於50歲及以上的成人，並已展現出令人鼓舞的成果。
Developed by Moderna, this vaccine represents a major shift in how we combat the seasonal flu.
針對4萬名參與者的臨床試驗顯示，與傳統選項相比，該疫苗在預防類流感疾病方面的效力提升了高達27%。
Initially designed for adults aged 50 and older, mFlusiva has shown promising results.
此疫苗真正的優勢在於其mRNA技術。
Clinical trials involving 40,000 participants revealed that it is up to 27% more effective at preventing flu-like illnesses compared to traditional options.
傳統流感疫苗通常在雞蛋中培養，這需要數月的時間。
The true strength of this vaccine lies in its mRNA technology.
相比之下，mFlusiva採用了「隨插即用」的設計，讓製造商能在短短六週內生產並更新疫苗，以匹配循環的病毒株。
Traditional flu vaccines are often grown in chicken eggs, a process that takes months.
儘管一些使用者可能會經歷疲勞或注射部位疼痛等常見副作用，但其整體安全性依舊良好。
In contrast, mFlusiva features a "plug-and-play" design, allowing manufacturers to produce and update the vaccine to match circulating virus strains in just six weeks.
儘管經歷了包含初步監管阻力的複雜批准過程，該疫苗目前已準備好在美國的2026–2027呼吸道季節發布。
While some users may experience common side effects like fatigue or injection site pain, the overall safety profile remains positive.
